<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="iso-abbrev">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of the American Pharmacists Association : JAPhA</journal-title></journal-title-group><issn pub-type="ppub">1544-3191</issn><issn pub-type="epub">1544-3450</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11903133</article-id><article-id pub-id-type="pmcid-ver">PMC11903133.1</article-id><article-id pub-id-type="pmcaid">11903133</article-id><article-id pub-id-type="pmcaiid">11903133</article-id><article-id pub-id-type="manuscript-id">NIHMS2045597</article-id><article-id pub-id-type="pmid">39733804</article-id><article-id pub-id-type="doi">10.1016/j.japh.2024.102318</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2045597</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2045597</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative Effectiveness of Buprenorphine Adherence with Telemedicine versus In-person for Rural and Urban Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Reese</surname><given-names initials="TJ">Thomas J.</given-names></name><degrees>PharmD, PhD</degrees><role>Assistant Professor</role><aff id="A1">Vanderbilt University Medical Center, Department of Biomedical Informatics, 2525 West End Avenue, Suite 1475</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Padi-Adjirackor</surname><given-names initials="NA">Nana Addo</given-names></name><degrees>MPH</degrees><aff id="A2">Vanderbilt University Medical Center, Department of Health Policy</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Griffith</surname><given-names initials="KN">Kevin N.</given-names></name><degrees>PhD</degrees><role>Assistant Professor</role><aff id="A3">Vanderbilt University Medical Center, Department of Health Policy</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Steitz</surname><given-names initials="B">Bryan</given-names></name><degrees>PhD</degrees><role>Assistant Professor</role><aff id="A4">Vanderbilt University Medical Center, Department of Biomedical Informatics</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patrick</surname><given-names initials="SW">Stephen W.</given-names></name><degrees>MD, MPH, MS</degrees><role>Professor and Chair</role><aff id="A5">Emory University, Rollins School of Public Health</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leech</surname><given-names initials="AA">Ashley A.</given-names></name><degrees>PhD, MS</degrees><role>Assistant Professor</role><aff id="A6">Vanderbilt University Medical Center, Department of Health Policy</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wiese</surname><given-names initials="AD">Andrew D.</given-names></name><degrees>PhD, MPH</degrees><role>Assistant Professor</role><aff id="A7">Vanderbilt University Medical Center, Department of Health Policy</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wright</surname><given-names initials="A">Adam</given-names></name><degrees>PhD</degrees><role>Professor</role><aff id="A8">Vanderbilt University Medical Center, Department of Biomedical Informatics</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="MV">Mauli V.</given-names></name><degrees>MPH</degrees><role>Health Services Research Analyst</role><aff id="A9">Vanderbilt University Medical Center, Department of Biomedical Informatics</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ancker</surname><given-names initials="JS">Jessica S</given-names></name><degrees>MPH, PhD</degrees><role>Professor</role><aff id="A10">Vanderbilt University Medical Center, Department of Biomedical Informatics</aff></contrib></contrib-group><author-notes><corresp id="CR1">Corresponding Author Fax: (615) 936-0102, <email>Thomas.Reese@vumc.org</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P18">Conflicts of Interest: The authors declare no relevant conflicts of interest or financial relationships.</p></fn></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><volume>65</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">484125</issue-id><fpage>102318</fpage><lpage>102318</lpage><pub-history><event event-type="nihms-submitted"><date><day>16</day><month>01</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-14 00:25:18.907"><day>14</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2045597.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">Policy changes during the COVID-19 pandemic allowed buprenorphine to be prescribed for opioid use disorder (OUD) via telemedicine without an in-person visit. A recently proposed change will limit buprenorphine access to 30 days without an in-person visit. Given that people living in rural areas may be disproportionally impacted by this change, we sought to better understand how buprenorphine adherence may be impacted by requiring in-person visits.</p></sec><sec id="S2"><title>Objective:</title><p id="P2">Compare buprenorphine adherence after telemedicine to adherence after in-person visits for patients who live in rural and urban areas.</p></sec><sec id="S3"><title>Methods:</title><p id="P3">In this retrospective cohort study, we used electronic health record data from a large medical center. The cohort included all adult patients prescribed buprenorphine for opioid use disorder during 2017&#8211;2022. The primary outcome was adherence, characterized by the Medication Possession Ratio (MPR) and gaps in buprenorphine treatment at 30 and 180 days. We conducted a longitudinal analysis at visit level, stratified by patient urbanicity, and controlled for patient, prescriber, prescription, and setting characteristics.</p></sec><sec id="S4"><title>Results:</title><p id="P4">From 511 patients, we followed 3302 in-person and 519 telemedicine visits. Compared to in-person visits we observed no difference in the adherence following telemedicine visits overall. However, telemedicine was associated with higher MPR for rural patients (30 days: adjusted marginal effects [AME], 3.7%; 95% CI, 2.0 to 5.5; P &lt; .001 and 180 days: AME, 8.5%; 95% CI 5.7 to 11.3; P &lt; .001) and fewer gaps (30 days: AME, &#8722;6.7%; 95% CI, &#8722;9.9 to &#8722;0.1; P &lt; .001 and 180 days: AME, &#8722;9.4%; &#8722;14.0 to &#8722;4.5; P &lt; .001) compared to in-person visits.</p></sec><sec id="S5"><title>Conclusions:</title><p id="P5">These findings suggest that telemedicine is a viable alternative to in-person visits, especially for patients living in rural areas, which should help guide future policies that preserve or increase access to buprenorphine in a manner that can reduce barriers for patients.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>